News

Ipsen has launched Dysport in the US for the treatment of cervical dystonia in adults. Dysport is the latest addition to the Ipsen’s drugs already available in North

Daiichi Sankyo has submitted an application in Japan to manufacture and market an injectable preparation of Levofloxacin Hydrate, that incorporates the company’s new quinolone anti-bacterial agent. Reportedly, the

Shire has reported study results on INTUNIV (guanfacine) Extended Release Tablets. INTUNIV was recently approved by the FDA as the first nonscheduled alpha-2A agonist indicated for the treatment

MAP Pharmaceuticals (MAP) has completed a planned interim safety review of the open-label, long-term safety extension of its phase 3 FREEDOM 301 clinical trial, with its Levadex orally

Novartis has shipped over 7.5 million doses of Influenza A(H1N1) vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in

Market research firm, Mintel has reported that because of the outbreak of H1N1 (swine flu), people around the world are flocking to drugstores and supermarkets to stock up

Cumberland Pharmaceuticals (Cumberland) and Phebra have entered into an exclusive partnership for the commercialization of Caldolor (ibuprofen) Injection in Australia and New Zealand. Caldolor, an intravenous formulation of

The FDA has issued a Complete Response Letter to Transcept Pharmaceuticals (Transcept) regarding the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual tablet). The NDA, submitted by

Roche has released the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research. The